2021
IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias
Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias. The American Journal Of Surgical Pathology 2021, 45: 1391-1398. PMID: 34172624, DOI: 10.1097/pas.0000000000001765.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaAcute monocytic leukemiaBlast countCore biopsyMyelomonocytic leukemiaBone marrowPredictive valueMonocytic leukemiaBone marrow core biopsiesCases of AMoLMarrow core biopsiesAcute myeloid leukemia subtypesExpression of IRF8Acute myeloid leukemiaTrephine core biopsiesReliable surface markersDendritic cell progenitorsNegative predictive valuePositive predictive valuePotential biomarker candidatesBlast increaseMonocytic blastsUseful immunostainsBlast percentageReactive monocytosis
2020
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications 2020, 11: 3549. PMID: 32669548, PMCID: PMC7363864, DOI: 10.1038/s41467-020-17175-8.Peer-Reviewed Original ResearchConceptsHER2-CAR T cellsCAR T cellsT-cell infusionCAR T-cell infusionT cellsMetastatic rhabdomyosarcomaOngoing phase I trialPhase I trialT cell receptorSecond remissionI trialSerum autoantibodiesImmune reactivityDetectable diseaseTumor responseBone marrowResponse consolidationInfusionRhabdomyosarcomaImmunodominant clonesLymphodepletionRemissionPathway proteinsDiseaseMonths
2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphoma